Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 13, 2016

View Archived Issues

FDA grants orphan drug status to BioVie's BIV-201 for ascites

Bristol-Myers Squibb initiates phase I/II trial of BMS-986183 in advanced hepatocellular carcinoma

GSK initiates phase II trial of GSK-2982772 in psoriasis

Oncology Venture incorporates oncology therapeutics spin-out 2X Oncology in U.S.

AdAlta signs manufacturing agreement for AD-114

FDA clears IND for phase I trial of Cantrixil in ovarian cancer

RespireRx announces preliminary topline data from phase IIa trial of CX-1739

Horizon Pharma to acquire Raptor Pharmaceutical

GlaxoSmithKline submits MAA for sirukumab in rheumatoid arthritis

Novel RBM20 gene mutation linked to left ventricular noncompaction cardiomyopathy

FDA gives fast track designation to niraparib, Tesaro begins rolling NDA submission

SK Biopharmaceuticals patents mGlu5 receptor PAMs

First patient dosed in Xencor's phase I study of Xmab-14045

Sunshine Lake Pharma and Calitor Sciences disclose PI3Kdelta inhibitors

Bayer Pharma describes anticancer agents

Bristol-Myers Squibb reports development of NS5B inhibitors

Amplyx Pharmaceuticals doses first patients in phase I study of antifungal agent

Janssen-Cilag submits MAA to EMA for darunavir-based single tablet regimen

MacroGenics regains rights to MGD-010 from Takeda

VCAM1 and ANGPTL4 show promise as successful pleurodesis biomarkers

Repros Therapeutics submits MAA for enclomiphene

Mutations in PRODH2 could be genetic cause of hydroxyprolinemia

PNPLA4 identified as novel causative gene for mitochondrial respiratory chain disorders

Janssen applies for emergency use assessment and listing of Ebola prime-boost vaccine regimen

FDA clears Angionetics' phase III study of Generx gene therapy

UD-009 shows efficacy in pulmonary fibrosis model

Interim topline data from phase Ib study of GED-0301 in active Crohn's disease

Brain penetration, effects on disease seen with SBC-103 in mucopolysaccharidosis IIIB

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.